Is CLX a good stock to buy right now?

Based on our 6-factor quantitative model, CLOROX CO /DE/ (CLX) receives a "Reduce" rating with a composite score of 43.9/100. It is ranked #2,501 out of 4,446 stocks. Key factor scores: Quality 50/100, Value 46/100, Momentum 34/100. The timing signal is "Neutral". This is quantitative analysis only — not investment advice.

What is the stock rating for CLX?

CLOROX CO /DE/ (CLX) has a "Reduce" rating and 2-star score. The composite score of 43.9 ranks it #2,501 among 4,446 U.S. stocks. Ratings are updated weekly using academically-proven factor models.

What sector is CLX in?

CLOROX CO /DE/ operates in the Consumer Discretionary sector (Consumer Goods industry) with a market cap of $12.60 billion. It is classified as a large-cap stock.

Does CLX pay a dividend?

CLX does not currently pay a regular dividend. The company may be reinvesting profits for growth.

What is CLX's P/E ratio?

CLX has a trailing P/E ratio of 19.84x. The Consumer Discretionary sector average is 24.5x. This P/E is in a moderate range relative to the broader market.

How profitable is CLX?

CLX's quality factor score is 50/100. Gross margin: 43.3%. ROE: 1794.3% vs sector average 6.2%. Margins are moderate to low, reflecting competitive market dynamics.

How is CLX valued compared to peers?

CLX's value factor score is 46/100 (higher = cheaper). Key multiples: P/E 19.8x, EV/EBITDA 15.3x. Valuation is roughly in line with peers.

What is CLX's debt level?

CLX's debt-to-equity ratio is 15937%. Sector average: 89%. Elevated leverage increases credit risk.

CLX has a beta of 0.35, meaning it is less volatile than the market. Stability score: 85/100.

Does CLX have high short interest?

CLX's short interest factor score is 15/100 (higher = less short selling). Elevated short interest may indicate bearish sentiment or short squeeze potential.

CLX Stock Analysis: Reduce (Score 43.9/100) | Blank Capital Research

Data Series	1D	5D	1M	YTD	1Y	3Y	5Y	10Y
CLX	-2.17%	+4.09%	-9.14%	+4.41%	-25.28%	-	-	-
Industry Proxy XLY	+0.13%	+4.38%	-1.35%	-5.46%	-39.92%	-	-	-
U.S. Market SPY	-0.07%	+3.60%	+0.34%	-0.36%	+29.52%	-	-	-
Alpha vs Market	-2.11%	+0.49%	-9.48%	+4.77%	-54.80%	-	-	-
Alpha vs Sector	-2.31%	-0.29%	-7.79%	+9.87%	+14.64%	-	-	-

Metric	CLX	Benchmark
P/E Ratio	19.8x	-19%
EV/EBITDA	15.3x	+212%
Price / Book	356.0x

Stock Entity	Score▼	Quality	Value	Momentum	P/E Ratio	ROE	Gross Margin	Net Margin	Rev Growth	D/E Ratio	Market Cap	Compare
CASY CASEYS GENERAL STORES INC	57	50	68	67	43.1x	16.9%	24.0%	3.8%	0.3%	123.0x	$27.2B	VS
TGT TARGET CORP	53	50	70	56	16.7x	20.7%	28.4%	3.4%	-0.7%	89.0x	$54.5B	VS
APEI AMERICAN PUBLIC EDUCATION INC	53	49	58	72	79.0x	4.6%	52.8%	2.1%	6.8%	32.0x	$1.1B	VS
LINC LINCOLN EDUCATIONAL SERVICES CORP	52	50	48	75	113.9x	5.6%	59.2%	2.3%	37.4%	147.0x	$1.3B	VS
FIVE FIVE BELOW, INC	52	50	56	73	106.3x	5.4%	32.5%	3.1%	26.5%	125.0x	$13.0B	VS
IMKTA INGLES MARKETS INC	51	50	51	62	17.7x	6.2%	23.9%	1.9%	0.4%	57.0x	$1.7B	VS
PRDO PERDOCEO EDUCATION Corp	51	50	70	57	14.1x	16.7%	100.0%	20.4%	27.1%	28.0x	$2.4B	VS
MCRI MONARCH CASINO & RESORT INC	51	50	66	47	16.6x	19.7%	24.5%	19.4%	11.5%	33.0x	$1.7B	VS
FCFS FirstCash Holdings, Inc.	49	50	29	66	35.4x	10.8%	50.2%	8.0%	26.6%	98.0x	$8.4B	VS
ESCA ESCALADE INC	48	50	65	51	15.6x	9.0%	26.1%	6.2%	8.4%	11.0x	$249M	VS
CLX CLOROX CO /DE/	44	50	46	34	19.8x	1,794.3%	43.3%	9.6%	-5.1%	15,937.0x	$12.6B

Key Ratio	TTM	2026	2025	2024	2023	2022	2021	2020	2019	2018	2017
Gross Margin %	0.4%	0.4%	0.5%	0.4%	0.4%	0.4%	0.4%	0.5%	0.4%	0.4%	0.4%
Operating Margin %	0.1%	0.1%	0.2%	0.1%	0.0%	0.1%	0.1%	0.2%	0.2%	0.2%	0.2%
EBITDA Margin %	0.1%	0.1%	0.2%	0.1%	0.0%	0.1%	0.2%	0.2%	0.2%	0.2%	0.2%
Net Margin %	0.1%	0.1%	0.1%	0.0%	0.0%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%
FCF Margin %	-	-	-	-	-	-	12.9%	19.2%	12.6%	12.8%	10.6%
ROE %	17.9%	4.6%	1.7%	0.6%	0.4%	0.6%	1.7%	1.0%	1.5%	1.1%	1.3%
ROA %	0.1%	0.0%	0.1%	0.1%	0.0%	0.1%	0.1%	0.2%	0.2%	0.2%	0.2%
ROIC %	1,835.1%	485.3%	28.7%	10.6%	6.6%	15.0%	25.5%	35.7%	28.4%	23.3%	28.8%

Key Ratio

TTM

2026

2025

2024

2023

2022

2021

2020

2019

2018

2017

Gross Margin %

0.4%

0.5%

0.4%

0.5%

0.4%

Operating Margin %

0.1%

0.2%

0.1%

0.0%

0.1%

0.2%

EBITDA Margin %

0.1%

0.2%

0.1%

0.0%

0.1%

0.2%

Net Margin %

0.1%

0.0%

0.1%

FCF Margin %

12.9%

19.2%

12.6%

12.8%

10.6%

ROE %

17.9%

4.6%

1.7%

0.6%

0.4%

0.6%

1.7%

1.0%

1.5%

1.1%

1.3%

ROA %

0.1%

0.0%

0.1%

0.0%

0.1%

0.2%

ROIC %

1,835.1%

485.3%

28.7%

10.6%

6.6%

15.0%

25.5%

35.7%

28.4%

23.3%

28.8%

Line Item	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
	$6.5B	$7.1B	$7.1B	$7.4B	$7.1B	$7.3B	$6.7B	$6.2B	$6.1B	$6.0B	$5.8B	$5.7B
	—	$3.9B	$4.0B	$4.5B	$4.6B	—	—	—	—	—	—	—
	$2.8B	$3.2B	$3.0B	$2.9B	$2.5B	$3.2B	$3.1B	$2.7B	$2.7B	$2.7B	$2.6B	$2.5B
Gross Margin	43.3%	45.2%	43.0%	39.4%	35.8%	43.6%	45.6%	43.9%	43.7%	44.7%	45.1%	43.6%
	—	$1.1B	$1.2B	$1.2B	$954M	—	—	—	—	—	—	—
Research & Development	—	$121M	$126M	$138M	$132M	$149M	$145M	$136M	$132M	$135M	$141M	$136M
Depreciation	—	—	—	—	—	$211M	$180M	$180M	$166M	$163M	$165M	$169M
Total Operating Expenses	—	$2.1B	$2.6B	$2.7B	$1.9B	—	—	—	—	—	—	—
	$813M	$1.1B	$398M	$238M	$607M	$927M	$1.3B	$1.1B	$1.1B	$1.1B	$1.1B	$1.0B
EBIT	$813M	$1.1B	$398M	$238M	$607M	$927M	$1.3B	$1.1B	$1.1B	$1.1B	$1.1B	$1.0B
EBITDA	$813M	$1.1B	$398M	$238M	$607M	$1.2B	$1.5B	$1.3B	$1.3B	$1.3B	$1.2B	$169M
Operating Margin	12.4%	15.2%	5.6%	3.2%	8.5%	12.6%	19.0%	18.1%	18.6%	18.9%	18.5%	17.8%
EBITDA Margin	12.6%	15.2%	5.6%	3.2%	8.5%	16.5%	21.8%	20.9%	21.3%	21.5%	21.5%	3.0%
	—	$88M	$90M	$90M	$106M	$99M	$99M	$97M	$85M	$88M	$88M	$100M
	—	$1.1B	$398M	$238M	$607M	—	—	—	—	—	—	—
Income Tax Expense	—	$254M	$106M	$77M	$136M	$181M	$246M	$204M	$231M	$330M	$335M	$315M
	$628M	$824M	$292M	$161M	$471M	$719M	$939M	$820M	$823M	$701M	$648M	$580M
Net Margin	9.6%	11.6%	4.1%	2.2%	6.6%	9.8%	14.0%	13.2%	13.4%	11.7%	11.3%	10.3%
	$1.29	$6.56	$2.26	$1.21	$3.75	$5.66	$7.46	$6.42	$6.37	$5.43	$5.01	$4.45
Diluted EPS	$1.29	$6.52	$2.25	$1.20	$3.73	$5.66	$7.46	$6.42	$6.37	$5.43	$5.01	$4.45
Weighted Avg Basic	—	124M	124M	124M	123M	—	—	—	—	—	—	—
Weighted Avg Diluted	—	124M	125M	124M	124M	—	—	—	—	—	—	—

Line Item

TTM

2025

2024

2023

2022

2021

2020

2019

2018

2017

2016

2015

$6.5B

$7.1B

$7.4B

$7.1B

$7.3B

$6.7B

$6.2B

$6.1B

$6.0B

$5.8B

$5.7B

—

$3.9B

$4.0B

$4.5B

$4.6B

—

$2.8B

$3.2B

$3.0B

$2.9B

$2.5B

$3.2B

$3.1B

$2.7B

$2.6B

$2.5B

Gross Margin

43.3%

45.2%

43.0%

39.4%

35.8%

43.6%

45.6%

43.9%

43.7%

44.7%

45.1%

43.6%

—

$1.1B

$1.2B

$954M

—

Research & Development

—

$121M

$126M

$138M

$132M

$149M

$145M

$136M

$132M

$135M

$141M

$136M

Depreciation

—

$211M

$180M

$166M

$163M

$165M

$169M

Total Operating Expenses

—

$2.1B

$2.6B

$2.7B

$1.9B

—

$813M

$1.1B

$398M

$238M

$607M

$927M

$1.3B

$1.1B

$1.0B

EBIT

$813M

$1.1B

$398M

$238M

$607M

$927M

$1.3B

$1.1B

$1.0B

EBITDA

$813M

$1.1B

$398M

$238M

$607M

$1.2B

$1.5B

$1.3B

$1.2B

$169M

Operating Margin

12.4%

15.2%

5.6%

3.2%

8.5%

12.6%

19.0%

18.1%

18.6%

18.9%

18.5%

17.8%

EBITDA Margin

12.6%

15.2%

5.6%

3.2%

8.5%

16.5%

21.8%

20.9%

21.3%

21.5%

3.0%

—

$88M

$90M

$106M

$99M

$97M

$85M

$88M

$100M

—

$1.1B

$398M

$238M

$607M

—

Income Tax Expense

—

$254M

$106M

$77M

$136M

$181M

$246M

$204M

$231M

$330M

$335M

$315M

$628M

$824M

$292M

$161M

$471M

$719M

$939M

$820M

$823M

$701M

$648M

$580M

Net Margin

9.6%

11.6%

4.1%

2.2%

6.6%

9.8%

14.0%

13.2%

13.4%

11.7%

11.3%

10.3%

$1.29

$6.56

$2.26

$1.21

$3.75

$5.66

$7.46

$6.42

$6.37

$5.43

$5.01

$4.45

Diluted EPS

$1.29

$6.52

$2.25

$1.20

$3.73

$5.66

$7.46

$6.42

$6.37

$5.43

$5.01

$4.45

Weighted Avg Basic

—

124M

123M

—

Weighted Avg Diluted

—

124M

125M

124M

—

CLOROX CO /DE/ (CLX) Stock Analysis — April 2026 Rating, Price, and Forecast

Last updated: April 2026

Company Overview — What Does CLOROX CO /DE/ Do?

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brand names; professional cleaning and disinfecting products under the CloroxPro, Clorox Healthcare, and Clorox Total 360 brand names; professional food service products under the Hidden Valley brand name; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brand names in the United States. The Household segment provides cat litter products under the Fresh Step, Scoop Away, and Ever Clean brand names; bags and wraps under the Glad brand name; and grilling products under the Kingsford and Kingsford Match Light brand names in the United States. The Lifestyle segment offers dressings, dips, seasonings, and sauces primarily under the Hidden Valley brand name; natural personal care products under the Burt's Bees brand name; and water-filtration systems and filters under the Brita brand name in the United States. The International segment provides laundry additives; home care products; water-filtration systems and filters; digestive health products; grilling products; cat litter products; food products; bags and wraps; natural personal care products; and professional cleaning and disinfecting products internationally primarily under the Clorox, Ayudin, Clorinda, Poett, Pine-Sol, Glad, Brita, RenewLife, Ever Clean and Burt's Bees brand names. The Clorox Company sells its products primarily through mass retailers, grocery outlets, warehouse clubs, dollar stores, home hardware centers, third-party and owned e-commerce channels, military stores, and distributors, as well as a direct sales force. The company was founded in 1913 and is headquartered in Oakland, California. CLOROX CO /DE/ (CLX) is classified as a large-cap stock in the Consumer Discretionary sector, specifically within the Consumer Goods industry. The company is led by CEO Linda Rendle and employs approximately 9,000 people, headquartered in Oakland, California. With a market capitalization of $12.6B, CLX is one of the prominent companies in the Consumer Discretionary sector.

CLOROX CO /DE/ (CLX) Stock Rating — Reduce (April 2026)

As of April 2026, CLOROX CO /DE/ receives a Reduce rating with a composite score of 43.9/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.CLX ranks #2,501 out of 4,446 stocks in our coverage universe. Within the Consumer Discretionary sector, CLOROX CO /DE/ ranks #258 of 442 stocks, placing it in the lower half of its Consumer Discretionary peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

CLX Stock Price and 52-Week Range

CLOROX CO /DE/ (CLX) currently trades at $105.28. The stock lost $2.34 (2.2%) in the most recent trading session. The 52-week high for CLX is $150.84, which means the stock is currently trading -30.2% from its annual peak. The 52-week low is $96.66, putting the stock 8.9% above its annual trough. Recent trading volume was 1.7M shares, reflecting moderate market activity.

Is CLX Overvalued or Undervalued? — Valuation Analysis

CLOROX CO /DE/ (CLX) carries a value factor score of 46/100 in the Blank Capital model, indicating fair valuation relative to historical norms. The trailing price-to-earnings ratio is 19.84x, compared to the Consumer Discretionary sector average of 24.47x — a discount of 19%. The price-to-book ratio stands at 355.96x, versus the sector average of 1.99x. The price-to-sales ratio is 1.93x, compared to 0.27x for the average Consumer Discretionary stock. On an enterprise value basis, CLX trades at 15.32x EV/EBITDA, versus 4.91x for the sector.

Overall, CLX's valuation appears roughly in line with sector benchmarks, suggesting the market is pricing the stock fairly given its current fundamentals and growth trajectory. Neither deep value nor significantly overpriced, the stock occupies a middle ground on valuation.

CLOROX CO /DE/ Profitability — ROE, Margins, and Quality Score

CLOROX CO /DE/ (CLX) earns a quality factor score of 50/100, indicating solid business quality with consistent operational execution. The return on equity (ROE) is 1794.3%, compared to the Consumer Discretionary sector average of 6.2%, which demonstrates strong shareholder value creation. Return on assets (ROA) comes in at 11.2% versus the sector average of 2.5%.

On a margin basis, CLOROX CO /DE/ reports gross margins of 43.3%, compared to 36.9% for the sector. The operating margin is 12.4% (sector: 3.8%). Net profit margin stands at 9.6%, versus 2.1% for the average Consumer Discretionary stock. Revenue growth is running at -5.1% on a trailing basis, compared to 3.3% for the sector. The overall profitability profile is adequate, though there may be room for margin expansion.

CLX Debt, Balance Sheet, and Financial Health

CLOROX CO /DE/ has a debt-to-equity ratio of 15937.0%, compared to the Consumer Discretionary sector average of 89.0%. This elevated leverage warrants close monitoring, as it increases the company's sensitivity to rising interest rates and economic downturns. The current ratio is 0.74x, which may signal near-term liquidity tightness.

CLX has a beta of 0.35, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for CLOROX CO /DE/ is 85/100, indicating low-volatility characteristics and consistent price behavior that appeals to risk-averse investors.

CLOROX CO /DE/ Revenue and Earnings History — Quarterly Trend

In TTM 2026, CLOROX CO /DE/ reported revenue of $6.46B and earnings per share (EPS) of $1.29. Net income for the quarter was $628M. Gross margin was 43.3%. Operating income came in at $813M.

In Q2 2026, CLOROX CO /DE/ reported revenue of $1.67B and earnings per share (EPS) of $1.29. Net income for the quarter was $161M. Gross margin was 43.2%. Revenue grew -0.8% year-over-year compared to Q2 2025. Operating income came in at $215M.

In Q1 2026, CLOROX CO /DE/ reported revenue of $1.43B and earnings per share (EPS) of $0.65. Net income for the quarter was $82M. Gross margin was 41.7%. Revenue grew -18.9% year-over-year compared to Q1 2025. Operating income came in at $107M.

In FY 2025, CLOROX CO /DE/ reported revenue of $7.10B and earnings per share (EPS) of $6.56. Net income for the quarter was $824M. Gross margin was 45.2%. Revenue grew 0.2% year-over-year compared to FY 2024. Operating income came in at $1.08B.

Over the past 8 quarters, CLOROX CO /DE/ has experienced revenue contraction from $7.09B to $6.46B. Investors analyzing CLX stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

CLX Dividend Yield and Income Analysis

CLOROX CO /DE/ (CLX) does not currently pay a dividend. This is common among growth-oriented companies in the Consumer Goods industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Consumer Discretionary dividend stocks may want to explore other Consumer Discretionary stocks or use the stock screener to filter by dividend yield.

CLX Momentum and Technical Analysis Profile

CLOROX CO /DE/ (CLX) has a momentum factor score of 34/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 35/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 15/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

CLX vs Competitors — Consumer Discretionary Sector Ranking and Peer Comparison

Within the Consumer Discretionary sector, CLOROX CO /DE/ (CLX) ranks #258 out of 442 stocks based on the Blank Capital composite score. This places CLX in the lower half of all Consumer Discretionary stocks in our coverage universe. Key competitors and sector peers include MONARCH CASINO & RESORT INC (MCRI) with a score of 50.5/100, CASEYS GENERAL STORES INC (CASY) with a score of 57.3/100, INGLES MARKETS INC (IMKTA) with a score of 51.0/100, FIVE BELOW, INC (FIVE) with a score of 51.6/100, and TARGET CORP (TGT) with a score of 52.6/100.

Comparing CLX against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full CLX vs S&P 500 (SPY) comparison to assess how CLOROX CO /DE/ stacks up against the broader market across all factor dimensions.

CLX Next Earnings Date

No upcoming earnings date has been announced for CLOROX CO /DE/ (CLX) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy CLX? — Investment Thesis Summary

The quantitative profile for CLOROX CO /DE/ suggests caution. Momentum is weak at 34/100, a headwind for near-term performance. Low volatility (stability score 85/100) reduces downside risk.

In summary, CLOROX CO /DE/ (CLX) earns a Reduce rating with a composite score of 43.9/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on CLX stock.

Related Resources for CLX Investors

Explore more research and tools: CLX vs S&P 500 comparison, top Consumer Discretionary stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare CLX head-to-head with peers: CLX vs MCRI, CLX vs CASY, CLX vs IMKTA.

Business quality

Valuation edge

Market alpha

Unlock Investment Thesis

Unlock Performance & Technicals

Unlock Valuation Tools

Institutional peer matrix

Dispersion: efficiency vs. valuation

Lateral intelligence network

Unlock Financial Statements

Unlock Ownership & Management

Intelligence Feed

Clorox Co. stock outperforms competitors on strong trading day

Clorox Co. stock underperforms Tuesday when compared to competitors

Clorox Co. stock underperforms Thursday when compared to competitors

The 3 Most Recession Resistant ETFs to Buy Ahead of Tariff Uncertainty

Wells Fargo Adjusts Price Target on Clorox to $110 From $125, Maintains Equalweight Rating

Unlock Earnings Transcripts

Institutional Intelligence FAQ

Related Research & Tools

Related Consumer Discretionary Stocks

CLOROX CO /DE/ (CLX) Stock Analysis — April 2026 Rating, Price, and Forecast

Company Overview — What Does CLOROX CO /DE/ Do?

CLOROX CO /DE/ (CLX) Stock Rating — Reduce (April 2026)

CLX Stock Price and 52-Week Range

Is CLX Overvalued or Undervalued? — Valuation Analysis

CLOROX CO /DE/ Profitability — ROE, Margins, and Quality Score

CLX Debt, Balance Sheet, and Financial Health

CLOROX CO /DE/ Revenue and Earnings History — Quarterly Trend

CLX Dividend Yield and Income Analysis

CLX Momentum and Technical Analysis Profile

CLX vs Competitors — Consumer Discretionary Sector Ranking and Peer Comparison

CLX Next Earnings Date

Should You Buy CLX? — Investment Thesis Summary

Related Resources for CLX Investors

Comments

Institutional Benchmarks

Get alerted on rating changes

Intelligence Feed

Clorox Co. stock outperforms competitors on strong trading day

Clorox Co. stock underperforms Tuesday when compared to competitors

Clorox Co. stock underperforms Thursday when compared to competitors

The 3 Most Recession Resistant ETFs to Buy Ahead of Tariff Uncertainty

Wells Fargo Adjusts Price Target on Clorox to $110 From $125, Maintains Equalweight Rating